114 related articles for article (PubMed ID: 24323031)
1. Reply to D. Serraino et al.
Partridge AH; Gelber S; Gelber R
J Clin Oncol; 2014 Jan; 32(2):161. PubMed ID: 24323031
[No Abstract] [Full Text] [Related]
2. Reply to A. Oguz et al.
O'Sullivan CC; Holmes E; Campbell C; Bradbury I; Zujewski JA; Gelber RD
J Clin Oncol; 2016 Feb; 34(6):640-1. PubMed ID: 26644531
[No Abstract] [Full Text] [Related]
3. Recurrence of breast cancer in elderly women.
Serraino D; Berretta M; Tirelli U
J Clin Oncol; 2014 Jan; 32(2):161. PubMed ID: 24323029
[No Abstract] [Full Text] [Related]
4. Reply to a. Avan et Al.
Baselga J; Clark E; Kiermaier A; Swain SM
J Clin Oncol; 2015 May; 33(15):1712. PubMed ID: 25870094
[No Abstract] [Full Text] [Related]
5. Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer.
Oguz A; Keskin GS; Colak D; Altundag O; Akcali Z
J Clin Oncol; 2016 Feb; 34(6):639-40. PubMed ID: 26644534
[No Abstract] [Full Text] [Related]
6. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
7. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.
de Vries CL; Linn SC; Brandsma D
J Neurooncol; 2016 Apr; 127(2):401-3. PubMed ID: 26732082
[No Abstract] [Full Text] [Related]
8. Breakthrough in breast cancer treatment. "Smart bullet" T-DM1 delivers a payload to cancer cells and avoids healthy ones.
Duke Med Health News; 2012 Aug; 18(8):3. PubMed ID: 23029673
[No Abstract] [Full Text] [Related]
9. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
10. Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
Gujral DM; Lloyd G; Bhattacharyya S
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):446-7. PubMed ID: 23583229
[No Abstract] [Full Text] [Related]
11. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
Cho WC; Roukos DH
Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
[No Abstract] [Full Text] [Related]
12. Neoadjuvant pertuzumab in early HER2-positive breast cancer.
Sekeres MA
Clin Adv Hematol Oncol; 2013 Dec; 11(12):799-800. PubMed ID: 24893285
[No Abstract] [Full Text] [Related]
13. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
Tuma RS
J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
[No Abstract] [Full Text] [Related]
14. Pertuzumab: increasing the options.
Nunes R; Swain SM
Oncology (Williston Park); 2014 Mar; 28(3):199, 204, 210. PubMed ID: 24855727
[No Abstract] [Full Text] [Related]
15. Hormone receptor status affects locoregional control in HER2-positive breast cancer treated with trastuzumab.
Barton MK
CA Cancer J Clin; 2012; 62(5):281-2. PubMed ID: 22847535
[No Abstract] [Full Text] [Related]
16. Neoadjuvant pertuzumab: the exception that proves the rule?
Burstein HJ
Oncology (Williston Park); 2014 Mar; 28(3):197-9. PubMed ID: 24855726
[No Abstract] [Full Text] [Related]
17. The promise of antibody-drug conjugates.
Teicher BA; Doroshow JH
N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386
[No Abstract] [Full Text] [Related]
18. HER2-positive breast cancer: a new piece of the puzzle.
Gnant M; Bartsch R; Steger GG
Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
[No Abstract] [Full Text] [Related]
19. Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.
Avan A; Avan A; Maftouh M; Ghayour Mobarhan M; Shahidsales S; Gholamin S
J Clin Oncol; 2015 May; 33(15):1711-2. PubMed ID: 25870088
[No Abstract] [Full Text] [Related]
20. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
Bonneterre ME; Bonneterre J
Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
